A  	A  	 DT	O
glimpse  	glimpse  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
future 	future 	 NN	O
:  	:  	 :	O
recombinant  	recombinant  	 JJ	O
proteins  	proteins  	 NNS	O
and  	and  	 CC	O
small  	small  	 JJ	O
molecules  	molecules  	 NNS	O
for  	for  	 IN	O
targeted  	targeted  	 JJ	O
therapies  	therapies  	 NNS	O
in  	in  	 IN	O
rheumatic  	rheumatic  	 JJ	B-NP
diseases  	diseases  	 NNS	I-NP
Whether  	Whether  	 IN	O
the  	the  	 DT	O
differences  	differences  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
picture  	picture  	 NN	I-NP
and  	and  	 CC	O
in  	in  	 IN	O
the  	the  	 DT	O
pathogenesis  	pathogenesis  	 NN	B-NP
between  	between  	 IN	O
rheumatoid  	rheumatoid  	 JJ	B-NP
arthritis  	arthritis  	 NN	I-NP
( 	( 	 -LRB-	O
RA 	RA 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
ankylosing  	ankylosing  	 JJ	B-NP
spondylitis  	spondylitis  	 NNS	I-NP
( 	( 	 -LRB-	O
AS 	AS 	 NNP	B-NP
)  	)  	 -RRB-	O
will  	will  	 MD	O
lead  	lead  	 VB	O
to  	to  	 TO	O
different  	different  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
approaches  	approaches  	 NNS	I-NP
is  	is  	 VBZ	O
unclear  	unclear  	 JJ	O
at  	at  	 IN	O
present 	present 	 JJ	O
.  	.  	 .	O
Since  	Since  	 IN	O
anti-TNF-alpha  	anti-TNF-alpha  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
and  	and  	 CC	O
other  	other  	 JJ	O
biologics  	biologics  	 NNS	B-NP
are  	are  	 VBP	O
not  	not  	 RB	O
efficacious  	efficacious  	 VBN	O
in  	in  	 IN	O
all  	all  	 DT	O
patients  	patients  	 NNS	O
new  	new  	 JJ	O
developments  	developments  	 NNS	B-NP
are  	are  	 VBP	O
clearly  	clearly  	 RB	O
needed 	needed 	 VBN	O
.  	.  	 .	O
